{"product_id":"merck-bcg-matrix","title":"Merck \u0026 Co. Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co.'s BCG Matrix offers a critical snapshot of its diverse product portfolio, highlighting areas of strength and potential concern. Understanding which products are Stars, Cash Cows, Dogs, or Question Marks is essential for strategic resource allocation and future growth. \u003c\/p\u003e\n\u003cp\u003eDive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeytruda (Pembrolizumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeytruda, Merck's monumental oncology drug, is a clear Star in the BCG Matrix.  Its 2024 sales reached an astounding $29.5 billion, cementing its position as the world's top-selling pharmaceutical.  This remarkable performance is fueled by its expanding use across numerous cancer types and new approvals for earlier treatment stages and combination therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWinrevair (Sotatercept)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWinrevair (sotatercept) is positioned as a Star in Merck \u0026amp; Co.'s BCG Matrix.  This groundbreaking treatment for pulmonary arterial hypertension (PAH) received FDA approval in March 2024, marking a significant expansion of Merck's cardiometabolic offerings.\u003c\/p\u003e\n\u003cp\u003eWith its broad label, Winrevair is expected to capture a substantial market share, driving considerable revenue growth. Merck anticipates sales to reach $4.9 billion by 2029, underscoring its high growth potential and market leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnimal Health Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck Animal Health is a significant player in the industry, showcasing robust growth. In 2024, the division achieved $5.9 billion in sales, marking a 4% increase year-over-year. This impressive performance was driven by strategic pricing adjustments, sustained demand for its products, and impactful acquisitions, including Elanco's aqua business.\u003c\/p\u003e\n\u003cp\u003eA standout performer within the portfolio is the Bravecto brand, which offers essential flea and tick preventives for companion animals. In 2024, Bravecto alone generated $1.1 billion in sales, underscoring its strong market position and continued consumer trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWelireg (Belzutifan)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWelireg (belzutifan) represents a strong contender within Merck \u0026amp; Co.'s oncology portfolio, particularly noted for its approval in treating tumors like pheochromocytoma or paraganglioma (PPGL) and specific kidney cancers. Its status as the sole oral, non-surgical treatment for PPGL in the U.S. highlights its unique market position and therapeutic advantage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Position:\u003c\/strong\u003e Welireg is a differentiated oncology asset, holding the distinction of being the only U.S.-approved oral, non-surgical treatment for PPGL.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth Potential:\u003c\/strong\u003e Clinical trial data suggests significant promise, positioning Welireg as a potential blockbuster therapy, contributing to Merck's revenue growth.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Importance:\u003c\/strong\u003e As a key oncology product, Welireg aligns with Merck's strategic focus on expanding its presence in high-need cancer treatment areas.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eENFLONSIA (Clesrovimab-cfor)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eENFLONSIA (Clesrovimab-cfor), a key product for Merck \u0026amp; Co., likely falls into the Stars category of the BCG Matrix. Its FDA approval in June 2025 for RSV prevention in infants marks a significant market entry.\u003c\/p\u003e\n\u003cp\u003eAs the first and only RSV preventive with a weight-independent dosing for infants, ENFLONSIA is positioned for high market share growth in a potentially expanding vaccine market.  Merck's investment in this innovative treatment underscores its high growth potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Entry:\u003c\/strong\u003e FDA approved June 2025 for RSV prevention in neonates and infants.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnique Selling Proposition:\u003c\/strong\u003e First and only RSV preventive with weight-independent dosing for infants.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Position:\u003c\/strong\u003e Strong potential for high market share and growth in the vaccines segment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck's Blockbusters: Keytruda Leads, Winrevair Soars!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co.'s Stars represent high-growth, market-leading products. Keytruda continues its dominance with $29.5 billion in 2024 sales, solidifying its position as the top-selling pharmaceutical globally. Winrevair, approved in March 2024 for pulmonary arterial hypertension, is projected to reach $4.9 billion in sales by 2029, indicating strong future growth. Merck Animal Health also demonstrates star qualities, with $5.9 billion in 2024 sales and a 4% year-over-year increase, driven by strategic acquisitions and product demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003e2024 Sales (Billions USD)\u003c\/td\u003e\n\u003ctd\u003eProjected Growth\/Market Position\u003c\/td\u003e\n\u003ctd\u003eSegment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda\u003c\/td\u003e\n\u003ctd\u003e29.5\u003c\/td\u003e\n\u003ctd\u003eWorld's top-selling pharmaceutical; expanding indications\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWinrevair\u003c\/td\u003e\n\u003ctd\u003eN\/A (Launched March 2024)\u003c\/td\u003e\n\u003ctd\u003eProjected $4.9 billion by 2029; first-in-class for PAH\u003c\/td\u003e\n\u003ctd\u003eCardiometabolic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerck Animal Health\u003c\/td\u003e\n\u003ctd\u003e5.9\u003c\/td\u003e\n\u003ctd\u003e4% YoY growth; strong demand and acquisitions\u003c\/td\u003e\n\u003ctd\u003eAnimal Health\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBravecto\u003c\/td\u003e\n\u003ctd\u003e1.1\u003c\/td\u003e\n\u003ctd\u003eKey product within Animal Health; strong consumer trust\u003c\/td\u003e\n\u003ctd\u003eAnimal Health\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWelireg\u003c\/td\u003e\n\u003ctd\u003eN\/A (Data not publicly available for 2024)\u003c\/td\u003e\n\u003ctd\u003eSole oral, non-surgical PPGL treatment in U.S.; potential blockbuster\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eENFLONSIA\u003c\/td\u003e\n\u003ctd\u003eN\/A (Approved June 2025)\u003c\/td\u003e\n\u003ctd\u003eFirst and only weight-independent dosing for RSV prevention in infants\u003c\/td\u003e\n\u003ctd\u003eVaccines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eMerck \u0026amp; Co.'s BCG Matrix analysis would detail its product portfolio, categorizing them as Stars, Cash Cows, Question Marks, or Dogs.\u003c\/p\u003e\n\u003cp\u003eThis framework would guide strategic decisions on investment, divestment, or holding for each business unit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Merck \u0026amp; Co. BCG Matrix offers a clear, one-page overview, relieving the pain of complex portfolio analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGardasil\/Gardasil 9\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGardasil\/Gardasil 9 stands as a prominent Cash Cow for Merck \u0026amp; Co., evidenced by its substantial $8.6 billion in sales for 2024. This human papillomavirus (HPV) vaccine is a cornerstone of Merck's revenue stream, demonstrating its established market dominance.\u003c\/p\u003e\n\u003cp\u003eDespite a slight 3% sales decrease in 2024, attributed to factors like reduced demand and a temporary shipment halt in China, Gardasil maintains a commanding market share. This dip highlights market-specific challenges rather than a weakening of the product's overall position in a mature market.\u003c\/p\u003e\n\u003cp\u003eMerck remains optimistic about Gardasil's future in China, viewing it as a crucial long-term growth market. This strategic outlook reinforces the product's status as a reliable Cash Cow, with potential for renewed growth as market conditions evolve.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJanuvia\/Janumet (Sitagliptin-based diabetes drugs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJanuvia and Janumet, Merck's sitagliptin-based diabetes medications, represent significant Cash Cows for the company. These established treatments have consistently generated substantial revenue, with sales reaching $5.2 billion in 2024. \u003c\/p\u003e\n\u003cp\u003eDespite facing patent expiry in January 2025, their strong market share in a mature diabetes market ensures continued, reliable cash flow generation for Merck. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLynparza (Olaparib)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLynparza, a key oncology drug co-developed with AstraZeneca, continues to be a significant revenue generator for Merck.  In the second quarter of 2025, alliance revenues for Lynparza reached $370 million, marking a robust 15% increase. This growth is attributed to escalating global demand for the PARP inhibitor.\u003c\/p\u003e\n\u003cp\u003eDespite its patent expiry looming in 2027, Lynparza demonstrates continued strength and market presence within the oncology sector. Its consistent performance solidifies its position as a valuable asset within Merck's portfolio, contributing substantially to alliance revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLenvima (Lenvatinib)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLenvima, a tyrosine kinase inhibitor developed with Eisai, is a significant oncology product for Merck \u0026amp; Co., generating consistent alliance revenues.  In the second quarter of 2025, alliance revenues for Lenvima reached $265 million, marking a 5% increase. This performance underscores its strong market position and contribution to Merck's stable cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct:\u003c\/strong\u003e Lenvima (Lenvatinib)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDeveloper:\u003c\/strong\u003e Merck \u0026amp; Co. (collaboration with Eisai)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQ2 2025 Alliance Revenue:\u003c\/strong\u003e $265 million\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Growth:\u003c\/strong\u003e 5%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMature Cardiovascular, Metabolism \u0026amp; Endocrinology Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMerck's Mature Cardiovascular, Metabolism \u0026amp; Endocrinology franchise is a strong cash cow within its BCG matrix. In 2024, this segment generated €2.9 billion in sales, demonstrating a robust 8.5% organic growth. This performance highlights the sustained demand for its established products in these critical therapeutic areas.\u003c\/p\u003e\n\u003cp\u003eThese established drugs operate in mature markets, which translates to reliable and predictable cash flow generation for Merck. Their strong market positions mean they require less intensive promotional spending compared to newer, less established products.\u003c\/p\u003e\n\u003cp\u003eThe franchise's success is underpinned by several key factors:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eConsistent Revenue Generation:\u003c\/strong\u003e The portfolio consistently contributes significant revenue, acting as a stable financial foundation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh Profitability:\u003c\/strong\u003e Mature products typically have lower R\u0026amp;D and marketing costs relative to their sales, leading to higher profit margins.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Leadership:\u003c\/strong\u003e Entrenched market positions allow for pricing power and sustained customer loyalty.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Importance:\u003c\/strong\u003e While mature, these franchises remain vital for Merck's overall market presence and financial stability, funding innovation in other areas.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiabetes Drugs Still Drive Billions Despite Patent Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck's established diabetes treatments, Januvia and Janumet, continue to be significant cash cows, generating $5.2 billion in sales in 2024. Despite patent expiries on the horizon in 2025, their strong market share in the mature diabetes market ensures continued, reliable cash flow for the company.\u003c\/p\u003e\n\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Sales (USD Billions)\u003c\/th\u003e\n\u003cth\u003eKey Characteristic\u003c\/th\u003e\n\u003cth\u003ePatent Expiry\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGardasil\/Gardasil 9\u003c\/td\u003e\n\u003ctd\u003e8.6\u003c\/td\u003e\n\u003ctd\u003eDominant HPV vaccine, mature market\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanuvia\/Janumet\u003c\/td\u003e\n\u003ctd\u003e5.2\u003c\/td\u003e\n\u003ctd\u003eEstablished diabetes medications, mature market\u003c\/td\u003e\n\u003ctd\u003eJanuary 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLynparza (Alliance Revenue)\u003c\/td\u003e\n\u003ctd\u003e~1.5 (estimated annual based on Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eKey oncology drug, strong growth\u003c\/td\u003e\n\u003ctd\u003e2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLenvima (Alliance Revenue)\u003c\/td\u003e\n\u003ctd\u003e~1.06 (estimated annual based on Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eOncology TKI, consistent revenue\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eMerck \u0026amp; Co. BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Merck \u0026amp; Co. BCG Matrix preview you are viewing is the identical, fully formatted document you will receive immediately after purchase. This comprehensive analysis, crafted by industry experts, will be delivered to you without any watermarks or demo content, ensuring you get a professional and actionable strategic tool. You can confidently use this preview as a direct representation of the complete, ready-to-implement BCG Matrix report that will be yours to download and utilize for your business planning. This ensures transparency and guarantees that the strategic insights you see are precisely what you will gain access to for immediate application. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610857554297,"sku":"merck-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/merck-bcg-matrix.png?v=1754747638","url":"https:\/\/growthsharematrix.com\/products\/merck-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}